## Background: As single agents, both paclitaxel and epirubicin in combination with cytokines can mobilize peripheral blood progenitor cells (pbpcs). the authors have demonstrated previously that the combination of epirubicin and paclitaxel is very active against metastatic breast carcinoma and tol
Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer
โ Scribed by Pedrazzoli, P; Perotti, C; Da Prada, GA; Bertolini, F; Gibelli, N; Torretta, L; Battaglia, M; Pavesi, L; Preti, P; Salvaneschi, L
- Book ID
- 109837387
- Publisher
- Nature Publishing Group
- Year
- 1997
- Tongue
- English
- Weight
- 995 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective st
## Abstract Serum circulating immune complexes (CIC) were repeatedly measured by means of the Cl binding assay (Cba) and the Raji cell assay (Rca) in 158 patients with metastatic breast cancer (mbc). Frequency of occurrence and levels of CIC were only slightly increased in mbc when compared to ageโ
## Abstract Recent research advances show that tumor cell intravasation (entry into the circulation) and metastasis occur very early in breast cancer progression. Clinical studies also illustrate the potential importance of detection of circulating tumor cells (CTCs) in outcomes of patients with me